Follow @ebcapital
Recent articles
Why Co-Diagnostics Skyrocketed 28.3% Today
The FDA has approved emergency use of its at-home COVID-19 test.
Why Alector Is Tumbling 28.7% Today
Investors appear nervous that COVID-19 precautions could create obstacles to trials evaluating its lead drug candidate.
Why Medpace Holdings Is Skyrocketing 13.5% Higher Today
The clinical trial company's second-quarter financial results were better than expected.
Jazz Pharmaceuticals Wins FDA Approval for Its New Narcolepsy Drug
Xywav has been shown to reduce both cataplexy and excessive daytime sleepiness in narcolepsy patients.
Why CytoSorbents Is Soaring 12% Today
The company has priced its recently announced stock offering.
Gilead Sciences Invests $300 Million in an Immuno-Oncology Startup
The biopharma giant is acquiring 49.9% of privately-held Tizona Therapeutics.
Here's Why OPKO Health's Stock Is Skyrocketing 23% Today
The company confirmed it will provide coronavirus testing for the National Football League.
Here's Why Tricida Is Tanking 38.5% Today
The FDA has noted deficiencies in the application for approval of its only drug in development.
Why Waters Stock Is Skyrocketing 12.9% Today
The healthcare company's second-quarter results appear better than expected.
Here's Why Dynavax Is Surging 6.1% Today
Enrollment has begun in an early stage coronavirus vaccine trial utilizing Dynavax's technology.
Blueprint Medicines Inks Deal With Roche Worth Up to $1.7 Billion
Roche is licensing commercial rights to Blueprint Medicines RET-inhibitor pralsetinib.
Why InMode Shares Are Soaring 13.7% Today
The medical device maker's boosting its second-quarter guidance.
Here's Why Retractable Technologies Is Skyrocketing 22% Today
The company's been awarded a multimillion-dollar government COVID-19 contract to expand production of needles and syringes.
GlaxoSmithKline Inks New COVID-19 Vaccine Research Pact
Medicago is using GlaxoSmithKline's vaccine adjuvant in its clinical-stage COVID-19 vaccine.
Turning Point Therapeutics Licenses Its Lung Cancer Drug in China
Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.
Why Bellus Health Stock Tanked 69.2% Today
The company's lead drug has failed a phase 2 trial.
Why MEI Pharma Is Tanking 15.3% Today
A trial evaluating its most advanced drug has been discontinued because of a lack of efficacy.
Why COVID-19 Vaccine Developer Dynavax Is Down 6.5% Today
Pfizer released intriguing data regarding its own COVID-19 vaccine.
Why Translate Bio Crashed 21% Today
The clinical-stage vaccine developer, which is working on a COVID-19 vaccine candidate, announced it's selling more shares to the public.
uniQure Inks $2 Billion Licensing Deal With CSL Behring
Agreement licenses the rights for a promising hemophilia B gene therapy.